FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 662 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR What Latino People Should Know About Quitting Smoking and Health Disparities:... November 18, 2021 Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... September 14, 2020 ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A... December 29, 2021 Patient Guide on Immunotherapy Side Effects and Their Management Now Available... April 29, 2026 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Encorafenib and Binimetinib A coming together of minds for early detection Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer...
